Gateway Investment Advisers LLC Has $3.04 Million Stake in Becton Dickinson and Co (BDX)

Share on StockTwits

Gateway Investment Advisers LLC decreased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 2.1% during the third quarter, HoldingsChannel.com reports. The firm owned 11,643 shares of the medical instruments supplier’s stock after selling 244 shares during the period. Gateway Investment Advisers LLC’s holdings in Becton Dickinson and were worth $3,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of BDX. Fundsmith Equity Fund L.P. purchased a new position in shares of Becton Dickinson and during the 2nd quarter valued at approximately $894,775,000. FMR LLC lifted its position in shares of Becton Dickinson and by 13.7% during the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock valued at $4,069,559,000 after buying an additional 2,049,874 shares in the last quarter. Charles Schwab Investment Advisory Inc. purchased a new position in shares of Becton Dickinson and during the 2nd quarter valued at approximately $291,167,000. Vontobel Asset Management Inc. lifted its position in shares of Becton Dickinson and by 823.0% during the 2nd quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock valued at $250,205,000 after buying an additional 904,097 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in shares of Becton Dickinson and by 186.5% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 414,119 shares of the medical instruments supplier’s stock valued at $99,206,000 after buying an additional 269,589 shares in the last quarter. 92.39% of the stock is currently owned by institutional investors and hedge funds.

Shares of BDX stock opened at $238.09 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. The firm has a market capitalization of $64.16 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 1.43 and a beta of 1.11. Becton Dickinson and Co has a fifty-two week low of $203.99 and a fifty-two week high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.86 by $0.05. The company had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The firm’s revenue for the quarter was up 41.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.46 EPS. Sell-side analysts expect that Becton Dickinson and Co will post 11.01 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 28th. Shareholders of record on Friday, September 7th were issued a $0.75 dividend. The ex-dividend date was Thursday, September 6th. This represents a $3.00 dividend on an annualized basis and a yield of 1.26%. Becton Dickinson and’s payout ratio is currently 31.65%.

A number of research analysts have recently issued reports on the company. Morgan Stanley increased their target price on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research report on Thursday, October 4th. Wells Fargo & Co increased their target price on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup increased their target price on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Royal Bank of Canada reiterated a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. Finally, KeyCorp reiterated a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $255.40.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Recommended Story: Why Dividend Stocks May Be Right for You

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

KLX Inc  Given Consensus Recommendation of “Hold” by Brokerages
KLX Inc Given Consensus Recommendation of “Hold” by Brokerages
AMN Healthcare Services  vs. R C M Technologies  Financial Contrast
AMN Healthcare Services vs. R C M Technologies Financial Contrast
Horizonte Minerals  Hits New 1-Year Low at $0.03
Horizonte Minerals Hits New 1-Year Low at $0.03
Avivagen  Reaches New 12-Month Low at $0.42
Avivagen Reaches New 12-Month Low at $0.42
FrankyWillCoin  Price Reaches $0.0034 on Exchanges
FrankyWillCoin Price Reaches $0.0034 on Exchanges
Bitcoin Zero Price Tops $0.0239
Bitcoin Zero Price Tops $0.0239


© 2006-2018 Ticker Report